12 Aug 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Taiwan-based ScinoPharm (Changshu) Pharmaceuticals and Shanghai-based Sundia MediTech entered in a strategic alliance to seek more opportunities for collaboration on contract research and manufacturing services (CRAMS) in mainland China.
This cooperation combines Sundia's diversified technical know-how and capabilities in new drug R&D with ScinoPharm's process R&D and commercial production advantages, especially in the field of highly potent oncological APIs. Under the alliance, both parties will be able to further support customer needs with one-stop solutions for integrated services such as drug development, research, clinical trials and commercial manufacturing.
Dr Jo Shen, CEO, ScinoPharm, Taiwan, and chairman, ScinoPharm Changshu, said that, "Resources from our Changshu site in Jiangsu province, China, and the Shanghai-based CRO company, Sundia will be combined to establish a robust collaboration with single-source solutions to address the increasing number of multinational companies shifting their drug development research and clinical trials in China."
Dr Chen Chen, CEO, Sundia, said that, "Sundia has established long-standing and strong relationships with a number of big pharmaceuticals and small/ medium-sized biotech companies from the US, Europe, Japan and South Korea in the fields of chemistry, biology, preclinical formulation and API manufacture, helping our clients and partners to bring drugs to the market efficiently."
"Sundia is very pleased to have the opportunity to work with ScinoPharm, a world-leading process R&D and API manufacturing service provider. I am sure that the strategic partnership between Sundia and ScinoPharm will have mutual benefits, helping each other to thrive in both international and China Market," added Dr Chen.